Receiver operating characteristic

New Study Finds Significant Correlation Between Masimo ORi™ and Arterial Partial Pressure of Oxygen During One-Lung Ventilation

Retrieved on: 
Monday, December 11, 2023
Biotechnology, Surgery, Health, Pharmaceutical, Health Technology, Odds ratio, Samsung Medical Center, De novo, Blood, OLV, Sungkyunkwan University, Hypoxemia, Risk, MASI, Patient, Multimedia, Journal, FDA, Hyperoxia, Oxygen, Blood gas tension, Perioperative, Ori, Oxygen saturation (medicine), Receiver operating characteristic, Medical device, Medical imaging, Anesthesia, ROC

ORi is trended continuously with SpO2 as a unit-less index between 0.00 and 1.00 to extend the visibility of the patient oxygenation beyond SpO2 under supplemental oxygen.

Key Points: 
  • ORi is trended continuously with SpO2 as a unit-less index between 0.00 and 1.00 to extend the visibility of the patient oxygenation beyond SpO2 under supplemental oxygen.
  • During anesthesia, ORi was monitored using Masimo RD rainbow SET® Pulse CO-Oximetry sensors, and blood gas analysis was performed 15 minutes after OLV was initiated.
  • Of the 11 potential predictors for PaO2
  • The researchers concluded, “ORi values during one-lung ventilation were significantly correlated with PaO2 measured simultaneously.

bioAffinity Technologies Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Patent, Use, Compensator (control theory), Journal of Visualized Experiments, Marketing, Respiratory Research, Clinical trial, Lung cancer, Receiver operating characteristic, Pulmonology, BIAF, Research, Lung, IPO, Flow cytometry, Treating, Patient, Physician, European, CFO, FDA, Therapy, Medical imaging, Medical device, Pharmaceutical industry, ROC

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three months ended March 31, 2023.

Key Points: 
  • bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three months ended March 31, 2023.
  • Highlights from the first quarter of 2023 and subsequent weeks included:
    Appointed Michael Dougherty as Chief Financial Officer.
  • Research and development expenses were $370,000 for the first quarter of 2023, compared with $280,000 for the comparable period in 2022.
  • Clinical development expenses were $20,000 for the first quarter of 2023, compared with $53,000 for the first quarter of 2022.

bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Friday, March 31, 2023
Science, Biotechnology, Research, Oncology, Health, Medical Devices, Clinical Trials, Other Health, Sputum, COPD, Survival rate, Exercise, IPO, LDT, American Lung Association, Physician, Communication, Survival, Food and Drug Administration, Respiratory Research, Cancer, Lung cancer, Receiver operating characteristic, Medicine, BIAF, Lung, Sale, Chronic obstructive pulmonary disease, Patient, Patent, Machine learning, Flow cytometry, Laboratory developed test, United Kingdom, Diagnosis, Porphyrin, Therapy, National Board of Medical Examiners, Food, Biopsy, Medical imaging, Security (finance), Pharmaceutical industry, Video game, Cryptocurrency, ROC

Revenue for the fourth quarter of 2022 was approximately $2,500, compared with no revenue for the prior-year period.

Key Points: 
  • Revenue for the fourth quarter of 2022 was approximately $2,500, compared with no revenue for the prior-year period.
  • Research and development expenses were $429,000 for the fourth quarter of 2022, compared with $318,000 for the comparable period in 2021.
  • General and administrative expenses were $1.2 million for the fourth quarter of 2022, compared with $341,000 for the comparable period in 2021.
  • bioAffinity Technologies believes that its available cash will be sufficient to fund planned operations for at least the next 12 months.

bioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath® Lung for Noninvasive Detection of Early-Stage Lung Cancer

Retrieved on: 
Tuesday, March 28, 2023
Other Health, Research, Radiology, Pharmaceutical, Oncology, Medical Devices, Genetics, Clinical Trials, Science, Biotechnology, Other Science, Health, Sputum, Senior, TCPP, Fluorescence, Clinical trial, Cancer, Lung cancer, Intelligence, Receiver operating characteristic, BIAF, Lung, Patient, Flow cytometry, Diagnosis, Therapy, Medical imaging, ROC, Journal of Visualized Experiments

(NASDAQ: BIAF; BIAFW) today announced the publication of a paper titled “Porphyrin-modified beads for use as compensation controls in flow cytometry” in the peer-reviewed Journal of Visualized Experiments (JoVE).

Key Points: 
  • (NASDAQ: BIAF; BIAFW) today announced the publication of a paper titled “Porphyrin-modified beads for use as compensation controls in flow cytometry” in the peer-reviewed Journal of Visualized Experiments (JoVE).
  • The paper describes the protocol for preparing porphyrin-labeled compensation beads to optimize the results of bioAffinity’s CyPath® Lung test to detect early-stage lung cancer.
  • bioAffinity Technologies has an international patent pending for the proprietary compensation beads and their use in flow cytometry.
  • TCPP preferentially binds to cancer and cancer-related cells in the sputum and fluoresces, which aids in the detection of early-stage lung cancer.

bioAffinity Technologies Appoints Julie Anne Overton Director of Corporate Communications

Retrieved on: 
Monday, February 13, 2023
Research, Medical Devices, Other Communications, Marketing, Communications, Biotechnology, Digital Marketing, Health, Science, Oncology, United States Forest Service, GE Capital, Physician, Flow cytometry, Receiver operating characteristic, Strategic planning, Communication, Trinity, Lung, News, Patient, Clinical trial, BIAF, Family, CBS News, Congress, Lung cancer, Partnership, Creativity, Machine learning, Environment, Press, Global health, Medical imaging, ROC

(NASDAQ: BIAF; BIAFW) today announced its commercialization team, including the addition of Julie Anne Overton, a veteran of print and broadcast journalism, corporate communications and federal public affairs, as bioAffinity Technologies’ Director of Communications, and the marketing and advertising firms of Havas Health & You and Trinity Life Sciences to help build the CyPath® Lung brand and position it for success in the cancer diagnostics sector.

Key Points: 
  • (NASDAQ: BIAF; BIAFW) today announced its commercialization team, including the addition of Julie Anne Overton, a veteran of print and broadcast journalism, corporate communications and federal public affairs, as bioAffinity Technologies’ Director of Communications, and the marketing and advertising firms of Havas Health & You and Trinity Life Sciences to help build the CyPath® Lung brand and position it for success in the cancer diagnostics sector.
  • CyPath® Lung is a non-invasive test that detects early-stage lung cancer by automated flow cytometry and machine learning.
  • Prior to joining bioAffinity Technologies, Ms. Overton managed a comprehensive public affairs program for the USDA Forest Service.
  • CyPath® Lung uses automated flow cytometry developed with machine learning to analyze patient samples to reliably predict the presence of lung cancer.

bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research

Retrieved on: 
Tuesday, January 24, 2023
Biotechnology, FDA, Health, Other Health, Radiology, Pharmaceutical, Surgery, Oncology, Other Science, Research, Medical Devices, Genetics, Science, Clinical Trials, Flow cytometry, Receiver operating characteristic, Adenocarcinoma, Publication, Carcinoma, Lung, Patient, Harvard Medical School, BIAF, Sputum, Lung cancer, Dana, Machine learning, Cancer, Doctor of Philosophy, MD, Medical imaging, ROC

(NASDAQ: BIAF; BIAFW) today announced publication of “ Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning ” detailing results of the Company’s clinical trial for its non-invasive diagnostic CyPath® Lung in Respiratory Research , one of the leading peer-reviewed open access journals in the field of respiratory medicine.

Key Points: 
  • (NASDAQ: BIAF; BIAFW) today announced publication of “ Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning ” detailing results of the Company’s clinical trial for its non-invasive diagnostic CyPath® Lung in Respiratory Research , one of the leading peer-reviewed open access journals in the field of respiratory medicine.
  • Overall, the test resulted in specificity of 88% and sensitivity of 82%, similar to far more invasive procedures currently used to diagnose lung cancer.
  • More than half of those in the cancer cohort had early Stage I or II lung cancer.
  • Instead, CyPath® Lung analyzes the lung micro-environment and identifies whole cell populations that indicate cancer is present in the lung.

Digital Health Platform Reduces Bipolar Disorder Symptoms in More Than Half of Users

Retrieved on: 
Wednesday, September 7, 2022
Chronic pain, AUC, UCL, Juli, CEO, University College London, Hospital, Receiver operating characteristic, Caregiver, Research, Comorbidity, Migraine, Air pollution, Altmann, Bipolar disorder, Doctor of Philosophy, Time, Canadian International Council, Associate, Behavior, Psychiatry, Mania, Manic, Randomized controlled trial, Suicide, Asthma, Grammatical mood, ASMR, ASRM, Depression, Hypomania, Patient, Prevalence, Hypertension, Population, Weather, Patient Health Questionnaire, Sleep hygiene, Health, Environment, Lithium, Medical device, Poultry, Pharmaceutical industry, Risk management, ROC, MD

BOSTON, Sept. 7, 2022 /PRNewswire/ -- juli, the AI-powered chronic condition platform, released the results of a first-of-its-kind analysis demonstrating a 55 percent reduction in the number of people with bipolar disorder who experience symptoms of mania after only eight weeks using the juli app.

Key Points: 
  • Bipolar disorder is a lifelong, recurrent, episodic illness with high rates of hospitalization, suicide and comorbidity.
  • As of July 2022, 2,987 people with bipolar disorder had downloaded the juli app.
  • Of those, 77% (2,300) confirmed that they had been diagnosed with bipolar disorder by a psychiatrist.
  • More than half indicated they had experienced bipolar disorder for more than five years and 65 percent were seeing a physician regularly.

Emergency Department Study Demonstrates Utility of MediPines AGM100 in Triaging COVID-19 Patients

Retrieved on: 
Thursday, June 16, 2022
Other Health, Other Science, Other Technology, Research, Insurance, Medical Devices, Infectious Diseases, Hospitals, Data Management, Professional Services, Science, Technology, Mobile, Wireless, Nursing, Cardiology, General Health, COVID-19, Health, Doctor of Philosophy, Triage, FDA, COVID-19, World, ATS, WHO, Method, UC San Diego Health, International Conference on Emerging Infectious Diseases, COPD, Gas, AUC, Hospital, American Thoracic Society, Physician, University, World Health Organization, ED, Receiver operating characteristic, UCSD, Medicine, Patient, University of California, San Diego Performance-Based Skills Assessment, Urinary tract infection, Conference, VO2 max, Risk, Pharmaceutical industry, Medical imaging, MD, COVID, ROC

The measurement of gas exchange impairment (known as Oxygen Deficit) helped physicians accurately determine the need for hospital admission and supplemental oxygen administration in the emergency department (ED).

Key Points: 
  • The measurement of gas exchange impairment (known as Oxygen Deficit) helped physicians accurately determine the need for hospital admission and supplemental oxygen administration in the emergency department (ED).
  • The data indicate that the AGM100 is useful for important hospital admission and supplemental oxygen administration decisions in COVID-19 patients.
  • Additionally, the authors found that the AGM100 is able to identify patients at risk prior to obvious clinical deterioration, in a non-invasive, point-of-care fashion.
  • This study demonstrates that the AGM100 has utility for physicians on the front lines of medicine to combat the rising chronic respiratory disease burden.

dxFeed Named Most Innovative Market Data Project by WatersTechnology Awards

Retrieved on: 
Tuesday, May 24, 2022
Technology, Professional Services, Other Technology, Finance, Open Trusted Technology Provider Standard, Inside Market Data, Index, OPRA, UOA, Research, Receiver operating characteristic, Industry, Waters (magazine), Machine learning, CEO, Cryptocurrency, ROC

We are proud to announce that dxFeed has been named Most Innovative Market Data Project in the WatersTechnology 2022 Inside Market Data & Inside Reference Data awards honors.

Key Points: 
  • We are proud to announce that dxFeed has been named Most Innovative Market Data Project in the WatersTechnology 2022 Inside Market Data & Inside Reference Data awards honors.
  • The awards also recognize industry excellence within market data, reference data, and enterprise data management.
  • The firm won in the Most Innovative Market Data Project category with dxFeed Unusual Options Screener .
  • Read more about the Inside Market Data & Inside Reference Data Awards 2022 winners here .